Biometal muscle to restore atrial transport function in a permanent atrial fibrillation animal model: a potential tool in the treatment of end-stage heart failure

European Journal of Cardio-thoracic Surgery

Volumn 37, Issue 4, 2010, Pages 870-874

  Tozzi, Piergiorgio ^a   Hayoz, Daniel ^b   Taub, Steven ^a   Muradbegovic, Mirza ^a   Rizzo, Elena ^a   von Segesser, Ludwig K ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

Artificial muscle; Atrial fibrillation; Chronic heart failure; Ventricular assist device

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIPUMP; CARDIOVASCULAR EQUIPMENT; CONTROLLED STUDY; EXPLANT; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART ATRIUM PACING; HEART EJECTION FRACTION; HEART FAILURE; HISTOLOGY; INFLAMMATION; INTRACARDIAC ECHOCARDIOGRAPHY; NONHUMAN; PACEMAKER; PRIORITY JOURNAL; SHEEP; SIMULATION;

ANIMALS; ATRIAL FIBRILLATION; ATRIAL FUNCTION, RIGHT; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; EQUIPMENT DESIGN; HEART ATRIA; HEART FAILURE; HEART-ASSIST DEVICES; HEMODYNAMICS; PACEMAKER, ARTIFICIAL; SHEEP; TRACE ELEMENTS;

EID: 77949485660     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.09.042     Document Type: Article

References (21)

1. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Aurora P., Christie J., Dobbels F., Rahmel A.O., Keck B.M., and Hertz M.I. Registry of the International Society for Heart Lung Transplantation. Twenty-fourth official adult heart transplant report-2007. JISHLT 26 (2007) 769-781
2. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
3. Hershberger R.E., Nauman D., Walker T.L., Dutton D., and Burgess D. Care processes and clinical outcomes continuous outpatient inotropic support in patients with end-stage heart failure. J Card Fail 9 (2003) 180-187
4. Cowie M.R., Mosterd A., and Wood D.A. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
5. Kopecky S.L., Gersh B.J., McGoon M.D., Whisnant J.P., Holmes D.R., Ilstrup D.M., and Frye R.L. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 317 (1987) 669-767
6. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
7. Naito M., David D., Michelson E.L., Schaffenburg M., and Dreifus L.S. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atriventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 106 (1983) 284-291
8. Tozzi P., Hayoz D., Thévenaz P., Roulet J.Y., Salchli F., and von Segesser L.K. Atria assist device to restore transport function of fibrillating atrium. Eur J Cardiothorac Surg 33 2 (2008) 263-267
9. Tozzi P., Hayoz D., Thévenaz P., Roulet J.Y., Salchli F., and von Segesser L.K. Artificial muscles to restore transport function of diseased atria. ASAIO 54 1 (2008) 11-13
10. Lietz K., Long J.W., Kfoury A.J., Slaughter M.S., Silver M.A., Milano C.A., Rogers J.G., Naka Y., Mancini D., and Miller L.W. Outcomes of left ventricular assist device as destination therapy in the post REMATCH era: implication for patient selection. Circulation 116 (2007) 497-505
11. Dries D.L., Exner D.V., Gersch B.J., Domanski M.J., Waclawiw M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Study of the left ventricular dysfunction. J Am Coll Cardiol 32 (1998) 695-703
12. Ramdas G., Pai R.G., and Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 30 7 (2007) 349-354
13. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzy J.L., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., and Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines and the European Society of Cardiology Committee for practice Guidelines. J Am Coll Cardiol 48 (2006) e149-e246
14. Tisdale J.E., Borzak S., Sabbah H.N., Shimoyama H., and Goldstein S. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure. J Card Fail 12 9 (2006) 747-751
15. Neuberger H.R., Mewis C., van Veldhuisen D.J., Schotten U., van Gelder I.C., and Allessie M.A. Management of atrial fibrillation in patients with heart failure. Böhm M Eur Heart J 28 November (21) (2007) 2568-2577
16. Yuda S., Nakatani S., Kosakai Y., Yamagishi M., and Miyatake K. Long-term follow-up of atrial contraction after the maze procedure in patients with mitral valve disease. J Am Coll Cardiol 37 6 (2001) 1622-1627
17. Lemola K., Desjardins B., Sneider M., Case I., Chugh A., Good E., Han J., Tamirisa K., Tsemo A., Reich S., Tschopp D., Igic P., Elmouchi D., Bogun F., Pelosi Jr. F., Kazerooni E., Morady F., and Oral H. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart Rhythm 2 September (9) (2005 Sep) 929-930
18. Sawyer P.N., Page M., Baseliust L., Mc Cool C., Lester E., Stanczewsky B., Srinivasan S., and Ramasami N. Further studies of nitinol wire as contractile artificial muscle for an artificial heart. Cardiovasc Dis Bulletin Texas Heart Institute 3 1 (1976) 65-78
19. Yambe T., Shiraishi Y., Yoshizawa M., Tanaka A., Abe K., Sato F., Matsuki H., Esashi M., Haga Y., Maruyama S., TaKagi T., Luo Y., Okamoto E., Kubo Y., Osaka M., Nanka S., Saijo Y., Mibiki Y., Yamaguchi T., Shibata M., and Nitta S. Artificial myocardium with an artificial baroreflex system using nanotechnology. Biomed Pharmacother 57 1 (2003) 122-125
20. Rose E.A., Gelijins A.C., Moscowitz A.J., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., Long J.W., Ascheim D.D., Tierney A.R., Levitan R.G., Watson J.T., Meier P., Ronans R.S., Shapiro P.A., Lazar R.M., Miller L.W., Gupta L., Frazier O.H., Desvigne-Nickens P., Oz M.C., and Poirier V.L. Long-term use of left ventricular assist device for end-stage heart failure. NEJM 345 20 (2001) 1435-1443
21. Miller L.W., Pagani F.D., Russell S.D., John R., Boyle A.J., Aaronson K.D., Conte J.V., Naka Y., Mancini D., Delgado R.M., MacGillivray T.E., Farrar D.J., and Frazier O.H. Use of a continuous flow device in patients awaiting heart transplantation. NEJM 357 (2007) 885-896